VANGUARD GROUP INC 13D and 13G filings for Pacific Biosciences of California, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-30 11:13 am Sale | 2025-03-31 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 16,263,411 5.460% | -1,379,340 (-7.82%) | Filing |
| 2024-11-12 4:43 pm Unchanged | 2024-09-30 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 17,642,751 6.470% | 0 (Unchanged) | Filing |
| 2024-11-04 10:47 am Sale | 2024-09-30 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 17,642,751 6.470% | -9,146,748 (-34.14%) | Filing |
| 2024-01-10 10:16 am Purchase | 2023-12-29 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 26,789,499 10.020% | 6,510,464 (+32.10%) | Filing |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 20,279,035 8.970% | 424,159 (+2.14%) | Filing |
| 2022-02-10 08:32 am Purchase | 2021-12-31 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 19,854,876 9.000% | 5,534,577 (+38.65%) | Filing |
| 2021-02-10 11:40 am Purchase | 2020-12-31 | 13G | Pacific Biosciences of California, Inc. PACB | VANGUARD GROUP INC | 14,320,299 7.700% | 6,443,814 (+81.81%) | Filing |